Volume 19, Number 3—March 2013
Characterization of Mycobacterium orygis
Highlight and copy the desired format.
|EID||van Ingen J, Brosch R, van Soolingen D. Characterization of Mycobacterium orygis. Emerg Infect Dis. 2013;19(3):521-522. https://dx.doi.org/10.3201/eid1903.121005|
|AMA||van Ingen J, Brosch R, van Soolingen D. Characterization of Mycobacterium orygis. Emerging Infectious Diseases. 2013;19(3):521-522. doi:10.3201/eid1903.121005.|
|APA||van Ingen, J., Brosch, R., & van Soolingen, D. (2013). Characterization of Mycobacterium orygis. Emerging Infectious Diseases, 19(3), 521-522. https://dx.doi.org/10.3201/eid1903.121005.|
To the Editor: We thank Gey van Pittius and colleagues for their addition to the markers that identify Mycobacterium orygis as a distinct subspecies in the M. tuberculosis complex (1). Its isolation from a wild buffalo broadens the host range of M. orygis. Gey van Pittius and colleagues raise 3 issues: the utility of the gyrBoryx single-nucleotide polymorphism (SNP) being equally specific as the reported SNP in Rv204238, the presence of genomic regions RD701 and RD702 in M. orygis, and the addition of the sequence type (ST) 701 spoligotype to M. orygis–specific spoligotypes.
We agree that use of the gyrBoryx mutation is more practical for routine daily use because this gene helps identify several subspecies of the M. tuberculosis complex. However, use of the partial Rv2042 sequencing is similarly practical because it can be combined with sequencing of the adjacent pncA gene, which enables identification of several M. tuberculosis complex species and some subspecies (i.e., M. orygis, M. bovis, M. canettii) (2), to identify the CAS genotype of M. tuberculosis (J. van Ingen, unpub. data) and, to some degree, assess susceptibility to pyrazinamide (3).
With the added data, we can conclude that M. orygis is an M. tuberculosis complex subspecies defined by the presence of genomic regions RD1, RD2, RD4, RD5a, RD6, RD13–RD16, RD701, and RD702, by the C-to-G SNP in mmpL6551, and by the deletion of regions RD3, RD5b, RD7-RD12, RDoryx_1, RDoryx_4, and RDoryx_wag22. Subspecies-specific SNPs are present in gyrB and Rv2042. Spoligotypes ST587, ST701, and closely related types are characteristic of M. orygis, and this subspecies yields 17–20 copies of insertion sequence 6110 and a distinct 24-locus variable number tandem repeats pattern (4,5). Given the rapid progress in genome sequencing, additional markers specific for the different subspecies will further enrich this panel of differences.
- Gey van Pittius NC, van Helden PD, Warren RM. Characterization of Mycobacterium orygis. Emerg Infect Dis. 2012;18:1708–9 .
- Huard RC, Fabre M, de Haas P, Oliveira Lazzarini LC, van Soolingen D, Cousins D, Novel genetic polymorphisms that further delineate the phylogeny of the Mycobacterium tuberculosis complex. J Bacteriol. 2006;188:4271–87.
- Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, Validation of pncA gene sequencing in combination with the MGIT method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2012;50:428–34.
- van Ingen J, Rahim Z, Mulder A, Boeree MJ, Simeone R, Brosch R, Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies. Emerg Infect Dis. 2012;18:653–5.
- Gey van Pittius NC, Perrett KD, Michel AL, Keet DF, Hlokwe T, Streicher EM, Infection of African buffalo (Syncerus caffer) by oryx bacillus, a rare member of the antelope clade of the Mycobacterium tuberculosis complex. J Wildl Dis. 2012;48:849–57.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Jakko van Ingen, Medical Microbiology, Radboud University Nijmegen Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: January 17, 2013
- Page last updated: January 17, 2013
- Page last reviewed: January 17, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)